Last reviewed 2026-05-27 · How we verify

Mobic (MELOXICAM)

Mobic (generic name: MELOXICAM) is a Nonsteroidal Anti-inflammatory Drug [EPC] Small molecule drug developed by Boehringer Ingelheim. It is currently FDA-approved (first approved 2000) for Juvenile rheumatoid arthritis, Osteoarthritis, Rheumatoid arthritis.

Meloxicam works by inhibiting the enzyme prostaglandin G/H synthase 2, which is involved in the production of prostaglandins that cause pain and inflammation.

Mobic, also known as meloxicam, is a small molecule that belongs to the class of inhibitors and specifically targets the prostaglandin G/H synthase 2 enzyme. It works by inhibiting cyclooxygenase-2, an enzyme involved in the production of prostaglandins, which are associated with pain and inflammation.

At a glance

Mechanism of action

Mechanism of Action. Meloxicam is nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of meloxicam, like that of other NSAIDs, may be related to prostaglandin synthetase (cyclo-oxygenase) inhibition.

Approved indications

• Juvenile rheumatoid arthritis
• Osteoarthritis
• Rheumatoid arthritis

Boxed warnings

• WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning . Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use ( 5.1 ) Meloxicam tablet is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ( 5.2 ) Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions ( 5.1 ) ]. Meloxicam tablet is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 ) ]. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions ( 5.2 ) ].

Common side effects

• Gastrointestinal
• Abdominal pain
• Diarrhea
• Dyspepsia
• Flatulence
• Nausea
• Dyspeptic signs and symptoms+
• Influenza-like illness
• Upper Respiratory tract infections-pathogen class unspecified+
• Joint related signs and symptoms+
• Headaches NOS
• Rash NOS

Drug interactions

• fluconazole
• voriconazole
• warfarin

Key clinical trials

• Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis (NA)
• Clinical Evaluation of Arthrocentesis, Combination of Platelet-Rich Plasma and Cyclooxygenase Enzyme-2 Inhibitor in Treatment of Temporo-Mandibular Joint Anterior Displacement (PHASE3)
• Comparison of Mesotherapy Treatment Doses in Patients With Chronic Non-Specific Neck Pain (NA)
• Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) (PHASE3)
• Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia (PHASE2)
• Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery (PHASE2)
• Phase 2B Upper Extremity Nerve Block Study (PHASE2)
• Bunionectomy Study for Postoperative Analgesia (EPOCH 1) (PHASE3)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Mobic CI brief — competitive landscape report
• Mobic updates RSS · CI watch RSS
• Boehringer Ingelheim portfolio CI

Frequently asked questions about Mobic

Related

• Drug class: All Nonsteroidal Anti-inflammatory Drug [EPC] drugs
• Target: All drugs targeting Prostaglandin G/H synthase 2
• Manufacturer: Boehringer Ingelheim — full pipeline
• Therapeutic area: All drugs in Immunology
• Indication: Drugs for Juvenile rheumatoid arthritis
• Indication: Drugs for Osteoarthritis
• Indication: Drugs for Rheumatoid arthritis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing